Abstract：【Objective】To investigate the detection and clinical significance of peripheral blood miRNA-218 and survivin gene expression in patients with acute myeloid leukemia(AML).【Methods】Eighty-six AML patients admitted to our hospital were selected as the observation group, and 20 healthy individuals undergoing physical examination in our hospital during the same period were selected as the control group. The relative expression levels of miRNA-218 and survivin in peripheral blood were compared between the two groups. The clinical data of the observation group were statistically analyzed to determine the relationship of the levels of miRNA-218 and survivin with the clinical efficacy and survival time of the patients.【Results】The level of miRNA-218 in the observation group was lower than that in the control group, while the level of the survivin gene was higher than that in the control group(both P<0.05). Among the observation group, patients with WBC ≥30×109/L had lower level of miRNA-218 and higher level of survivin compared to patients with WBC <30×109/L, with statistically significant differences(P<0.05). The miRNA-218 level in the remission group was higher than that in the non-remission group, while the survivin level was lower in the remission group compared to the non-remission group(both P<0.05). The median survival times for the high and the low miRNA-218 expression groups were 17.00 months and 14.00 months, respectively, with statistically significant differences in the cumulative survival curves between the two groups(P<0.05). The median survival times for the high and the low survivin expression groups were 18.00 months and 20.00 months, respectively, with statistically significant differences in the cumulative survival curves between the two groups(P<0.05).【Conclusion】 miRNA-218 is lowly expressed and the survivin gene is highly expressed in the peripheral blood of AML patients. Both are important factors associated with poor clinical efficacy and prognosis in AML patients.
梁倩, 刘珍珍, 王晴晴. 急性髓系白血病患者外周血miRNA-218及survivin基因表达的临床意义*[J]. 医学临床研究, 2024, 41(6): 827-830.
LIANG Qian, LIU Zhenzhen, WANG Qingqing. Detection and Clinical Significance of Peripheral Blood miRNA-218 and Survivin Gene Expression in Patients with Acute Myeloid Leukemia. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 827-830.
[1] 徐静茹,杨大恒,龙广凤,等. m6A甲基化调控基因与儿童急性髓细胞白血病预后相关性的研究[J].中华预防医学杂志,2021,55(8):983-989. [2] 张小可,李明花,苑晓磊. CAG和HAG方案治疗急性髓细胞白血病患者的临床效果及毒副反应[J].解放军医药杂志,2020,32(9):18-21. [3] 胡霞,陈乃耀. 急性髓系白血病化疗合并感染的危险因素及风险评估[J].临床血液学杂志,2021,34(3):215-219. [4] 马薇,张改玲,张薇,等. 异基因造血干细胞移植对第一次形态学完全缓解急性髓系白血病患者预后的影响研究[J].湖南师范大学学报(医学版),2021,18(2):209-213. [5] 要兆旭,韩海平,冯志星. 喉癌组织中miR-34a和Survivin表达与临床病理特征和预后的关系[J].中国临床研究,2020,33(2):145-149. [6] TONG X Z, YANG P, WANG K Y, et al. Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218[J].Oncol Lett,2019,18(1):359-367. [7] 中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J].中华血液学杂志, 2023,44(9):705-712. [8] 张之南 沈悌. 血液病诊断及疗效标准[M].3版.北京:科学出版社, 2007:41-43. [9] 杨艳丽,李甜甜,耿英华,等. RUNX1基因突变对成人急性髓细胞白血病的预后有不良影响[J].南方医科大学学报,2020,40(11):1601-1606. [10] 储小燕,方洋,黄欧平. Survivin基因表达及其调控宫颈癌细胞增殖机制的研究[J].实用癌症杂志,2021,36(9):1434-1437. [11] SATO K, OSAKA E, FUJIWARA K,et al. miRNA-218 targets multiple oncogenes and is a therapeutic target for osteosarcoma[J].Oncol Rep,2022,47(5):92-103. [12] 熊雅红, 王翠, 李彬,等. Survivin和Aurora-b表达对喉癌诊断及病情评估的临床意义[J].实用癌症杂志, 2020, 35(8):341. [13] 要兆旭,冯志星,彭丽娜,等. miR-218和Survivin基因/蛋白在喉癌中的表达及其与喉癌化疗敏感性的关系[J].疑难病杂志,2019,18(11):1128-1133. [14] 李广平,张红心,张蕾,等. 非小细胞肺癌存活素蛋白和VEGF表达与HPV感染的关系[J].中华医院感染学杂志,2021,31(4):544-548.
2024, Vol. 41 
